Haemonetics Corp HAE
Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. 10-K, Item 1
- Headquarters
- Boston, MA
- CEO
- Christopher Simon
- Next results
- around Feb 4, 2027
Where each dollar of revenue went, FY2026
Revenue of $1.3B through the costs to a net profit of $97.3M · income statement of the 10-K
HAE among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.
What changed
4 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed May 20, 2026 against May 21, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
11 checks on the latest 10-K. Checks, not verdicts.
1fact worth reading about the other 10 checks found nothing to note
-
Critical audit matters changedNew this year: Valuation of goodwill (“As described in Note 10 to the consolidated financial statements, the Company had approximately $656 million of goodwill allocated among its reporting units as of March 28, 2026. The Company performs its annual impairment analysis as of the first day of the fourth quarter, and more frequently if the”). Same as last year: Business combination
-
Receivables +7.0% ($202.7M to $216.9M) vs revenue -2.0% ($1.4B to $1.3B), +9.0 pts apart
9 more checks with nothing to note
-
Cash from operations $293.2M vs net income $97.3M (FY ending Mar 28, 2026)
-
Inventory -16.1% ($365.1M to $306.4M) vs revenue -2.0% ($1.4B to $1.3B), -14.1 pts apart
-
Same auditor in both 10-Ks: Ernst & Young LLP
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
4 paragraphs in Risk Factors that were not in the 10-K filed May 21, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed May 21, 2025 10-K, ITEM 1A
An inability to successfully manage the implementation of our new global enterprise resource planning system could adversely affect our operations and operating results. We are in the process of implementing a new global enterprise resource planning system. This system will replace many of our existing operating and financial systems.…
-
Item 1A · new paragraph · not in the 10-K filed May 21, 2025 10-K, ITEM 1A
Additionally, FDA and foreign regulations and guidance are often revised or reinterpreted by the FDA and foreign counterparts in ways that may significantly affect our business and our products. Any new statutes, regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of…
-
Item 1A · new paragraph · not in the 10-K filed May 21, 2025 10-K, ITEM 1A
The One Big Beautiful Bill Act (“OBBBA”) was enacted in the U.S. on July 4, 2025. The OBBBA legislation provides for the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act of 2017, revisions to the international tax framework and the reinstatement of favorable tax treatment for certain business provisions.…
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
| Revenue | $1.2B | $1.3B | $1.4B | $1.3B |
| Net income | $115.4M | $117.6M | $167.7M | $97.3M |
| Operating cash flow | $273.1M | $181.8M | $181.7M | $293.2M |
| Free cash flow | $81.7M | $143.6M | $142.4M | $260.4M |
Revenue, FY2017 to FY2026
Ten fiscal years, each from its own 10-K · XBRL · USD
$1.3B ▼ 2.0% in FY2026$97.3M ▼ 42.0% in FY2026$260.4M ▲ 82.8% in FY2026
Recent filings
3 filings in the last 30 days · SEC EDGAR
-
Planned saleNov 12, 2026Maunsell Farris Maryanne (Officer) gave notice of a planned sale of 836 shares worth about $101K Form 144, approximate sale date Nov 11, 2026
-
8-KNov 5, 2026Quarterly results 8-K item 2.02
-
10-QNov 5, 2026Quarterly report (10-Q) period ended Sep 26, 2026
About the company
Haemonetics Corp, Boston, MA · from the 10-K filed May 20, 2026
Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components. When used in this report, the terms “we,” “us,” “our,” “Haemonetics” and the “Company” mean Haemonetics Corporation.
- Headquarters
- Boston, MA
- Country
- United States
- Reports in
- USD
- Listed on
- NYSE
- Fiscal year ends
- April 3
- Last results
- Nov 5, 2026
- Incorporated in
- MA
Email alerts
Sources
The 10-K filed May 20, 2026 (open at SEC), compared with the 10-K filed May 21, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/HAE/export.csv") into a cell.